{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/VRXA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Veraxa Biotech AG - Post de-SPAC (NASDAQ: VRXA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Veraxa Biotech AG - Post de-SPAC, listed on NASDAQ under ticker VRXA, with ISIN USH9130A1037. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-V8. The security type is Non-operating entity type (other), the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Switzerland. The segment is not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 50 filings in the twelve months to 2026-11-08, across 28 filing days. By type, the record holds 13 directors_dealings, 9 prospectus, 19 regulatory_filing and 9 results filings. The median gap between filing days is 4 days. The latest filing is dated 2026-10-29 and is of type directors_dealings, 10 days before the record date. The NASDAQ peer median is 6.0 days cadence, 52 filings and 5.0 days latency across 4359 issuers. The sector peer median is 6.0 days cadence, 63.0 filings and 4.0 days latency across 526 issuers.\n\n## Auditor\n\nThe auditor is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and foreign private issuers and older filings carry none. The auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds listing lines dated 2026-06-09, 2026-06-10 and 2026-06-10. The record holds no delisting and no name change. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client_categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the investor-relations pages read. The count is 0.\n\n## Open research\n\nNo openly published research notes were found. The count is 0.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer's years sealed are 2025 and 2026. The market's vintage is sealed, with earliest sealed date 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0002079109.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/VRXA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/VRXA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/VRXA",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "directors_dealings": 13,
    "prospectus": 9,
    "regulatory_filing": 19,
    "results": 9
   },
   "cadence_median_gap_days": 4,
   "filing_days": 28,
   "filings": 50,
   "latency_days": 10,
   "latest": [
    {
     "category": "4",
     "date": "2026-10-29",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000182912626011778/xslF345X06/ownership.xml",
     "title": "4 — FORM 4",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-10-21",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000182912626011387/xslF345X06/ownership.xml",
     "title": "4 — FORM 4",
     "type": "directors_dealings"
    },
    {
     "category": "6-K",
     "date": "2026-10-15",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000182912626011185/veraxabiotechag_6k.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "3",
     "date": "2026-09-14",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000182912626010085/xslF345X06/ownership.xml",
     "title": "3 — FORM 3",
     "type": "directors_dealings"
    },
    {
     "category": "424B3",
     "date": "2026-09-04",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000182912626009754/veraxabiotechag_424b3.htm",
     "title": "424B3 — 424B3",
     "type": "prospectus"
    }
   ],
   "latest_filing_date": "2026-10-29",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VRXA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "USH9130A1037"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002079109.json",
    "state": "sourced",
    "value": "Switzerland"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-V8",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002079109.json",
    "state": "sourced",
    "value": "Veraxa Biotech AG - Post de-SPAC"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002079109.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002079109.json",
    "state": "sourced",
    "value": "Non-operating entity type (other)"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "VRXA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2026-06-09",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000182912626006236/veraxabiotech_8-a12b.htm",
     "title": "8-A12B — 8-A12B"
    },
    {
     "date": "2026-06-10",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000135445726000557/VRXA_8A_Cert_0002079109.pdf",
     "title": "CERT"
    },
    {
     "date": "2026-06-10",
     "source": "https://www.sec.gov/Archives/edgar/data/2079109/000182912626006302/veraxabiotech_8-a12ba.htm",
     "title": "8-A12B/A — 8-A12B/A"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:39a00e34937ff0a62ac83017c539d9d7a1ecc3b32281fe81f5e04e6ba940ecdc",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/VRXA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:39a00e34937ff0a62ac83017c539d9d7a1ecc3b32281fe81f5e04e6ba940ecdc",
 "path": "/us/NASDAQ/VRXA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Veraxa Biotech AG - Post de-SPAC, listed on NASDAQ under ticker VRXA, with ISIN USH9130A1037. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-V8. The security type is Non-operating entity type (other), the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Switzerland. The segment is not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 50 filings in the twelve months to 2026-11-08, across 28 filing days. By type, the record holds 13 directors_dealings, 9 prospectus, 19 regulatory_filing and 9 results filings. The median gap between filing days is 4 days. The latest filing is dated 2026-10-29 and is of type directors_dealings, 10 days before the record date. The NASDAQ peer median is 6.0 days cadence, 52 filings and 5.0 days latency across 4359 issuers. The sector peer median is 6.0 days cadence, 63.0 filings and 4.0 days latency across 526 issuers.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and foreign private issuers and older filings carry none. The auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds listing lines dated 2026-06-09, 2026-06-10 and 2026-06-10. The record holds no delisting and no name change. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client_categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the investor-relations pages read. The count is 0.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found. The count is 0.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer's years sealed are 2025 and 2026. The market's vintage is sealed, with earliest sealed date 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0002079109.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VRXA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/VRXA"
  }
 ],
 "title": "Veraxa Biotech AG - Post de-SPAC (VRXA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}